Clinical

Dataset Information

0

A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors


ABSTRACT: Background: Combinations of dendritic and cytokine-induced killer cell (D-CIK) based adoptive immunotherapy and anti-PD-1 antibody may enhance the immune response and stop cancer cells from growing. Objective: Phase II clinical trial to investigate the safety, clinical activity and toxicity of combinations of D-CIK and anti-PD-1 antibody in patients with treatment-refractory solid tumors. Methodology: Phase II clinical trial in patients with advanced metastatic hepatocellular carcinoma, renal cell carcinoma,bladder cancer,colorectal cancer,non-small-cell lung cancer,breast cancer and other solid cancers. The D-CIK was isolated from peripheral blood of participants,then activated,expanded and incubated with anti-PD-1 antibody before infusion. The enough number (1.0-1.5 *10^10 cells) of D-CIK were infused back into participants.

DISEASE(S): Carcinoma,Colorectal Cancer,Carcinoma, Renal Cell,Bladder Cancer,Non-small-cell Lung Cancer,Renal Cell Carcinoma,Breast Cancer,Hepatocellular Carcinoma

PROVIDER: 2223938 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2011-04-29 | E-GEOD-28940 | biostudies-arrayexpress
2011-04-29 | GSE28940 | GEO
2022-09-12 | GSE212740 | GEO
2023-02-01 | GSE220670 | GEO
2021-07-13 | GSE154538 | GEO
2021-07-13 | GSE154536 | GEO
| 2272861 | ecrin-mdr-crc
2020-08-27 | GSE149479 | GEO
| phs001493 | dbGaP
2016-08-04 | E-GEOD-67501 | biostudies-arrayexpress